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Anti-vascular endothelial growth factor treatment for
eye diseases
Treatment is clearly effective but important clinical and public health implications remain
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Decades of research into angiogenesis have led to a triumph in
medical intervention with the development of anti-vascular
endothelial growth factor (VEGF) treatment for eye diseases.
Intraocular administration of anti-VEGF agents, principally
ranibizumab (Lucentis) and bevacizumab (Avastin), has
revolutionised the treatment of several common eye diseases
that lead to blindness, including age related macular
degeneration (AMD), diabetic retinopathy, and retinal vein
occlusion.1-3 The increased use of these agents in ophthalmology
has enabled patients with these eye diseases to preserve or regain
useful vision. Emerging evidence indicates that such treatment
may account for much of the falling incidence of blindness in
some developed countries over the past few years.4
The exponential rise in the use of anti-VEGF drugs for treating
eye disease has far reaching implications,5 but what are the key
messages for patients and their doctors? Firstly, patients should
present early when their vision is affected. There is evidence
that earlier treatment results in better outcomes.6 Secondly,
ocular anti-VEGF treatment is not a cure, although it provides
effective control of the disease by inhibiting abnormal growth
and leakage of small vessels in the eye. Thus, many patients
require long term repeated intraocular injections, sometimes as
often as monthly, to maintain their vision. Thirdly, each injection
carries a small risk of complications. Sight threatening
complications are rare, but include infection (endophthalmitis),
bleeding (vitreous haemorrhage), cataract, glaucoma, and retinal
detachment.7
However, three areas of uncertainty in the use of anti-VEGF
agents to treat eye disease remain. Firstly, systemic safety has
been a focal point of controversy.8 The intravenous
administration of anti-VEGF agents in patients with cancer has
a known risk of serious adverse events, including death.
Although the dose of anti-VEGF agents used for treating eye
disease is minute compared with that used intravenously, there
is evidence of systemic absorption and diffuse inhibition of
VEGF. Clinical case series have noted antiangiogenic effects
(such as regression of neovascularisation), not only in the treated
eye but also in the untreated eye after bevacizumab injections.8
Moreover, case-control studies have shownmarked suppression
of plasma VEGF concentrations after bevacizumab injections.9
Although recent systematic reviews that include clinical trial
data for ranibizumab suggest that serious adverse events are
rare,7 some studies signal a possible risk of thromboembolic
and non-ocular haemorrhagic events (such as stroke).10 It is
unclear whether these associations are causal, given the elderly
populations included in these trials and the small number of
events. As for bevacizumab, its systemic safety is even more
elusive because of the limited trials available and its
pharmacokinetic properties (such as longer half life), which in
theory may increase the risk of systemic adverse events.8
Cost effectiveness is the second area under the spotlight. At
present, the cost of the two anti-VEGF agents used most
commonly in ophthalmology varies widely. Ranibizumab could
be as much as 40 times more expensive than bevacizumab, its
off-label alternative. Cost effectiveness analysis suggests that
the use of ranibizumab is not justifiable unless it is 2.5-fold
more efficacious than bevacizumab.11 As the Comparison of
AMD Treatment Trial indicates, this is not the case.1 Its first
year results showed that ranibizumab and bevacizumab were
similarly effective in treating neovascular age related macular
degeneration. With around 25 000 new cases of this disease
diagnosed in the United Kingdom annually, replacing
ranibizumab with bevacizumab as standard treatment for these
cases could save close to £300m (€368m; $485m) a year.11
The third area relates to the dosing schedule of anti-VEGF
treatment for eye disease. The current standard regimen, derived
from landmark clinical trials of age related macular
degeneration, involves monthly injections. The Comparison of
AMD Treatment Trial, however, found equivalent efficacy for
monthly and as needed treatment regimens of ranibizumab, with
less conclusive results for bevacizumab.1Withmonthly clinical
assessment aided by investigative imaging (for example, optical
coherence tomography), the as needed regimen almost halved
the number of injections given. Such an approach is therefore
an acceptable way to reduce not only the burden of cost and
dannycheung@hotmail.com
For personal use only: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;344:e2970 doi: 10.1136/bmj.e2970 (Published 1 May 2012) Page 1 of 2
Editorials
EDITORIALS
treatment but also the patient’s risk of treatment related adverse
events.
A new antiangiogenic agent is also on the horizon. On the basis
of two phase III randomised controlled trials, the US Food and
DrugAdministration has recently approved the use of intraocular
aflibercept injection (VEGF Trap-Eye or Eylea) for patients
with neovascular age related macular degeneration.12 The first
year results of these trials showed that VEGF Trap-Eye and
ranibizumab injections had equivalent efficacy and safety
profiles.12 Although the cost per dose ($1850) is only slightly
less than that of ranibizumab, the less frequent dosing regimen
of VEGF Trap-Eye (two monthly injections after three initial
monthly injections) could avoid the need for costly and time
consuming monthly clinic visits for patients and their care
givers.
Indeed, the therapeutic prospects of major retinal diseases have
never been brighter since the advent of ocular anti-VEGF
treatment. In view of the rapidly evolving clinical and economic
issues, formulating evidence based treatment recommendations
is not a trivial task and requires science and regulation to
advance in concert. Nevertheless, the modern era of ocular
anti-VEGF treatment marks an important milestone in our battle
against blindness.
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